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Background: Hunter Syndrome is an X-linked lysosomal storage disorder due to the deficit of iduronate 2-sulfatase, an
enzyme catalysing the degradation of the glycosaminoglycans (GAG) dermatan- and heparan-sulfate. Treatment of the
disease is mainly performed by Enzyme Replacement Therapy (ERT) with idursulfase, in use since 2006. Clinical efficacy
of ERT has been monitored mainly by the Hunter Outcome Survey (HOS) while very few independent studies have
been so far conducted. The present study is a 3.5-years independent follow-up of 27 Hunter patients, starting ERT
between 1.6 and 27 years of age, with the primary aim to evaluate efficacy of the therapy started at an early age
(<12 years).
Methods: In this study, we evaluated: urinary GAG content, hepato/splenomegaly, heart valvulopathies,
otorinolaryngological symptoms, joint range of motion, growth, distance covered in the 6-minute walk test,
neurological involvement. For data analysis, the 27 patients were divided into three groups according to the age
at start of ERT: ≤5 years, >5 and ≤ 12 years and > 12 years. Patients were analysed both as 3 separate groups and
also as one group; in addition, the 20 patients who started ERT up to 12 years of age were analysed as one group.
Finally, patients presenting a “severe” phenotype were compared with “attenuated” ones.
Results: Data analysis revealed a statistically significant reduction of the urinary GAG in patients ≤5 years and ≤ 12
years and of the hepatomegaly in the group aged >5 and ≤ 12 years. Although other clinical signs improved in
some of the patients monitored, statistical analysis of their variation did not reveal any significant changes
following enzyme administration. The evaluation of ERT efficacy in relation to the severity of the disease evidenced
slightly higher improvements as for hepatomegaly, splenomegaly, otological disorders and adenotonsillar
hypertrophy in severe vs attenuated patients.
Conclusions: Although the present protocol of idursulfase administration may result efficacious in delaying the
MPS II somatic disease progression at some extent, in this study we observed that several signs and symptoms did
not improve during the therapy. Therefore, a strict monitoring of the efficacy obtained in the patients under ERT is
becoming mandatory for clinical, ethical and economic reasons.
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Hunter Syndrome (Mucopolysaccharidosis type II, MPS
II) is a rare, X-linked, inherited, lysosomal storage dis-
order with an estimated incidence of 1.3 in 100.000
male newborns [1]. It is due to the deficit of activity of
the lysosomal enzyme iduronate 2-sulfatase (IDS), nor-
mally degrading heparan- and dermatan-sulfate within
lysosomes. Insufficient or, commonly, totally absent
levels of IDS activity lead to progressive accumulation
of these GAG species in nearly all cell types, tissues, and
organs of the body, including respiratory tract, heart,
liver, spleen, bones, joints, oropharynx, head, neck,
leptomeninges and central nervous system (CNS) [2].
Hunter Syndrome is always a progressive, chronic and
life-threatening condition. Clinical manifestations vary
considerably from patient to patient. However, two major
phenotypes are formally recognized, a severe and an atten-
uated form, mainly differing for the lack of the CNS in-
volvement in the latter, also characterized by a slower
progression of the disease. Onset of signs and symptoms
typically occurs between 18 months and 4 years of age in
the severe phenotype and about 2 years later in the atten-
uated form [2-4]. The most common peripheral clinical
signs and symptoms include coarse facial features, hearing
loss, restrictive lung disease, hepato/splenomegaly, heart
valvulopathy, decreased joint range of motion, skeletal de-
formities and short stature. In addition, oropharyngeal
and respiratory deposition of GAG leads to severe airways
obstruction, further contributing to impaired pulmonary
function and sleep apnoea. About two-thirds of the pa-
tients present involvement of the CNS, leading to progres-
sive severe mental retardation, often in association with
communicating hydrocephalus and increased intracranial
pressure, which may also affect the attenuated forms [5].
Due to a combination of the bone disease, decreased re-
spiratory capacity and sleep apnoea, together with im-
paired cardiac function, patients with Hunter Syndrome
suffer from chronic, severely impaired endurance. As dis-
ease progresses their ability to walk may be partially lost
or for many patients totally lost. In the later stages of the
disease, the continuous accumulation of GAG leads to
progressive organ failure and significantly shortened life-
span. Death usually occurs in the second or third decade
of life or even later for the attenuated forms, most often
from respiratory and/or cardiac failure [2,3].
Haematopoietic transplant, applied mainly in the past,
has shown poor results [6,7]. The full cloning of the IDS
sequence has allowed the production of the recombinant
form of the enzyme and its administration with an En-
zyme Replacement Therapy (ERT) protocol. ERT was fully
licensed for MPS II by the USA FDA in 2006 and in the
same year Italy was the first country in Europe to provide
the drug to the patients. Since the first clinical trial, per-
formed in the USA in 2005, the Hunter Outcome Survey(HOS), supported by Shire HGT, Inc., has collected data
on Hunter patients under ERT with the objective to define
the natural history of the disease and to monitor safety/ef-
ficacy of the treatment. However, several aspects still need
to be fully evaluated. One of the principal issues to address
is to understand whether the treatment started at an early
age might result in a better prognosis. As stated by Muen-
zer [8] the rationale of an early initiation of ERT is sup-
ported by several observations: demonstrated lysosomal
GAG storage in prenatal age, improvements in preco-
ciously treated animal models, case reports of siblings
treated at different ages, etc. The Phase I/II and II/III clin-
ical trials enrolled only patients older than 5 years and
able to comply with the repeated pulmonary function and
endurance testing [9,10]. Recently, two studies [11,12] on
children younger than 6 years were published with data
from HOS. In the first study [11] 6 children who started
ERT from 2.8 to 4.7 years of age, treated for a mean period
of 9 months, evidenced some beneficial effects from ERT.
Reduction in urinary GAG levels, small reductions in liver
and spleen volumes, improvement or stabilization of joint
mobility were the main observed effects. The second study
[12] included 124 patients younger than 6 years at start of
therapy and followed for a mean period of 23 months;
however, this study only provided data related to urinary
GAG levels, hepatomegaly and antibodies response. In
addition, a multicentre open-label study [13] conducted
by Shire in children aged 1.4 to 7.5 years, evidenced a
safety profile similar to that observed in patients ≥5 years
and reduction of liver and spleen size and of urinary GAG
after 1 year of treatment. Finally, a study on patients under
1 years of age was recently performed by Lampe [14] and
colleagues evidencing, after a treatment longer than 6
weeks, an improvement or a stabilization of some somatic
symptoms. Instead, very few independent investigations
have been so far conducted; among these, a recent British
study funded by the Health Technology Assessment
(HTA) program [15]. The study recruited 36 paediatric
patients aged < 16 years (range 2.3-15.6) and 3 adults, and
evaluated Forced Vital Capacity (FVC), mobility, 6-
Minute Walking Test (6MWT), height, weight, hearing,
heart valve disease, carpal tunnel syndrome and spleen
and liver size, after 12 and 24 months of therapy. Data
analysis revealed only a statistically significant association
between duration of ERT and height measurements.
The present study, supported by AIFA (Italian Medi-
cines Agency), is the first independent data collection
carried on for a quite long time (about 3.5 years) after
the start of idursulfase ERT. It has the aim to evaluate
the efficacy of the recombinant enzyme administration,
by analysing several clinical and laboratory parameters
in a paediatric population aged between 1.6 and 12 years
at start of ERT, together with an additional Hunter
group starting ERT between 12 and 27 years of age.
Tomanin et al. Orphanet Journal of Rare Diseases 2014, 9:129 Page 3 of 16
http://www.ojrd.com/content/9/1/129Methods
Study inclusion criteria and clinical data collection
Twenty-seven patients were progressively enrolled in the
study from six different Clinical Units according to the
following inclusion criteria: diagnosis of MPS II confirmed
by low/absent IDS activity in leukocytes or fibroblasts, a
normal activity of other sulphatases, thus excluding mul-
tiple sulphatase deficiency, high levels of heparan- and
dermatan-sulphate in urine.
Informed consent to the participation in the study was
obtained from the patients or their legal tutors, who
maintained at any time full possibility to retire their con-
sent with no interruption of the appropriate medical
care and ERT administration.
The study was previously submitted to the Institu-
tional Review Board/Ethical Committee of each single
Clinical Unit which gave ethical approval to the enroll-
ment of the patients in the study:
 Azienda Ospedaliera di Padova - Comitato Etico
(approval date: 15/09/2008)
 Azienda Ospedaliera “Pugliese-Ciaccio” Catanzaro -
Comitato Etico (approval date: 06/06/2009)
 Università degli Studi di Napoli Federico II - Comi-
tato Etico per le Attività Biomediche (approval date:
30/09/2009)
 Azienda Ospedaliero-Universitaria “Policlinico Vit-
torio Emanuele” Catania - Comitato Etico (approval
date: 27/06/2011)
 Azienda Ospedaliero-Universitaria Meyer Firenze -
Comitato Etico per la Sperimentazione dei Medici-
nali (approval date: 16/09/2011)
 Azienda Ospedaliera San Gerardo Monza - Comi-
tato Etico (approval date: 15/12/2011).
Idursulfase (Elaprase®, Shire Human Genetics Therapies
Inc., USA) was weekly infused in 3 hours time at the dos-
age of 0.5 mg/kg of body weight, appropriately diluted in
0.9% sodium chloride according to producer’s indication.
At each infusion, vital signs were assessed in four different
moments: immediately prior to infusion, after an hour of
infusion, at the end of the infusion and one hour later.
In addition to ERT, each patient continued to receive the
appropriate medications, previously established, to manage
chronic or acute symptoms related to the disease.
The criteria for selection of the clinical outcome measures
or variables for the assessment of ERT efficacy were guided
by the principle that only those indicators reflecting the ex-
tent of disease progression could be useful to determine the
efficacy of the treatment.
As for laboratory parameters, the evaluation of urinary
GAG content was performed.
For the clinical assessments, evaluation of the presence/
absence of specific signs and symptoms were performedbefore the beginning of ERT, during ERT at determined
time-intervals and at the end of the follow-up. The follow-
ing signs and symptoms were evaluated: hepatomegaly
and splenomegaly (assessed through abdomen ultra-
sound), heart valvulopathies (through echocardiography),
otological disorders, adenotonsillar hypertrophy and the
related sleep disturbances (through audiometric and oto-
laryngological evaluations), joint range of motion (through
orthopaedic and physiatric evaluations). The neuroradio-
logical alterations typical of the disorder [white matter
abnormalities (WMAs), cerebral atrophy, ventricular
dilation, perivascular alteration] were evidenced through
neuroimaging. Different cognitive tests were administered
according to the patient’s age and disease severity, 6MWT
was administered only in collaborating patients. In
addition, height and weight measures were collected.
In addition to previously listed variables, we also regis-
tered other data including routine laboratory haemato-
chemical parameters, raising of anti-IDS antibodies,
pubertal development, measurement of head circumfer-
ence, eye evaluation. All data were collected through a
Case Report Form (CRF) previously approved by our In-
stitutional Review Board.
A follow-up was conducted for an average of 3.3 ± 1.5
years (median = 3.3 years). Pre-ERT evaluations were
considered those taken as proximate as possible to the
start of ERT, while as last we chose evaluations closest
to 3.5 years from the start of the therapy, when available.
While the total number of enrolled patients was 27, not
all of them were included in each evaluation; conse-
quently, the total number of patients analysed ranges
from 9 to 25, according to the variable considered.
Criteria for data analysis
Due to the lack of a comprehensive reconstruction of
the natural history of the disease, and to the unavailabil-
ity of a control ERT naive group (Hunter patients not
undergoing ERT), we considered the treatment effective
when it determined “an improvement in or a prevention
of progression of disease activity as indicated by a
stabilization in clinical condition together with an im-
provement in the abnormalities present at baseline” as
suggested by Vellodi et al. 2010 [16].
For data analysis, two different stratifications of the
patients were performed: by age at start of ERT and by
disease severity.
As for the age at start of ERT, the following groups
were considered:
1. group A (≤5 years, n = 13), group B (>5 and ≤ 12
years, n = 7), group C (>12 years, n = 7) separately
analysed;
2. patients ≤12 years of age taken together (group A +
B; n =20);
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+ C; n = 27).
As for disease severity, patients were divided according
to their “severe” or “attenuated” phenotype as previously
described [4].
All analyses were performed by comparing pre-ERT
with post- ERT data.
Statistical data analysis
Since urinary GAG were measured by applying different
methodologies and measurement units by the different
Operative Units, the percentage ratio of each considered
time-point from pre-ERT baseline value, taken as 100%,
was calculated. The analysis was conducted with the
Wilcoxon signed rank test at 1, 2 and 3 years post-ERT
and at the last available evaluation.
Data related to hepatomegaly, splenomegaly, oto-
logical disorders, adenotonsillar hypertrophy, sleep
disturbances, CNS abnormalities by brain imaging, cog-
nitive function involvement and seizure were reported
as dichotomous variables representing the presence or
the absence of a given pathological phenotype before
treatment and at the end of the study. The variation
pre-post treatment was analysed with the McNemar
test. Therapeutic efficacy was evaluated as proportion of
positive outcomes, intended as the number of patients
for which the pathological phenotype was improved
(feature present before the start of therapy and disap-
peared after treatment) plus those patients for which
the phenotype did not worsen (feature absent both be-
fore and after therapy). The confidence intervals for this
proportion was calculated by the method of Clopper
and Pearson [17].
As valvulopathies we considered valve regurgitation of
each cardiac valve, and reported its severity according to
the scale suggested by Zoghbi [18].
For joint mobility, therapeutic efficacy was also evalu-
ated by assigning a judgment of stabilization (s), worsen-
ing (w) or improvement (i) of the clinical status of the
patient with respect to the pre-ERT situation, taking into
account the evaluations of joint range of motion and all
inherent available data in the orthopaedic history of each
patient. The proportions of each of these classes (s, w, i)
are reported with confidence intervals calculated as
above.
Growth was evaluated by z-score (Standard Devi-
ation Score, SDS) calculated for each height and weight
measurements using the 2000 Centre for Disease
Control LMS parameters (http://www.cdc.gov/growth-
charts/percentile_data_files.htm) according to the for-
mula reported by Cole and Green [19]. A first order
autoregressive model, AR(1), was used to analyse the
growth data.In the 6MWT performance, the distance covered by the
patients under study was compared with normal values
for children aged 4–11 taken from Lammers, 2008 [20].
All statistical tests were conducted at the level of signifi-
cance of 5%. Due to the exploratory hypothesis-generating
rather than hypothesis-testing nature of the study, no cor-
rection to the p-values was applied for the multiplicity of
the analyses taken.
Results
Main features of the population examined
Twenty-seven patients were enrolled. All patients com-
pleted the study, except one because of his exitus caused by
cardiopulmonary arrest at 25 years of age.
Basic information related to the 27 patients enrolled is
reported in Table 1. Most patients presented with a se-
vere phenotype (17 out of 27), 10 showed an attenuated
phenotype. The genetic characterization revealed 14 dif-
ferent missense, 3 nonsense and 2 splicing mutations, 3
small and 1 large deletions, and 1 IDS-IDS2 recombin-
ation. In only one patient the mutation was not identi-
fied. In the cohort of patients analysed, two couples of
siblings were present (A3 and A11; A7 and A10). Apart
from siblings, all patients, except 2, showed different
mutations. The only 2 non-sibling patients carrying the
same genomic variant (B5, C7) presented an attenuated
and a severe phenotype, respectively.
The age at diagnosis was available for 25 patients and
ranged from 0.9 to 15.5 years (median 3.5). The age at
start of ERT was between 1.6 and 27 years with a me-
dian age of 5.3.
Urinary glycosaminoglycan levels
Figure 1 reports urinary GAG levels measured at several
time-points in the course of the follow-up for the 3 groups
of patients. Data were collected for a median time of 3.2
(0.4-3.8), 3.6 (3.3-3.8) and 3.4 (2.7-3.6) years for groups A,
B and C respectively, for 25 out of 27 patients.
Table 2 reports the results of the statistical data ana-
lysis performed on GAG percentage variation calculated
with respect to pre-ERT GAG values.
The variations in GAG levels resulted significant at
each time-point when considering all patients together
and the group of patients up to 12 years of age at start
of ERT. The separate evaluation of each age group also
gave statistically significant results at all time-points only
for group A; evaluations of group B was significant after
1 year of treatment and at the last evaluation, while for
group C data were not statistically significant at all the
time-points considered.
Hepatomegaly and splenomegaly
The absence-presence of hepatomegaly and splenomegaly,
evidenced by abdominal ultrasound, before the beginning
Table 1 Characteristics of the patients enrolled in the study
Patient ID Phenotype Type of mutation Age at diagnosis Age at start of ERT
Group A
A1 Severe Intragenic deletion 0.9 1.6
A2 Severe Missense 1.0 1.6
A3 Severe Missense 2.2 2.3
A4 Attenuated Small deletion 1.8 2.4
A5 Attenuated Splicing mutation 2.4 2.6
A6 Severe Small deletion 2.8 2.9
A7 Attenuated Two in cis missense 1.3 3.3
A8 Severe Missense 2.8 3.4
A9 Severe Splicing mutation 3.2 3.4
A10 Attenuated Two in cis missense n.a. 3.7
A11 Severe Missense 3.5 3.7
A12 Severe Missense 4.4 4.7
A13 Severe Missense 4.7 5.0
Group B
B1 Severe Small deletion 2.5 5.3
B2 Attenuated Nonsense n.a. 6.9
B3 Severe Missense 2.2 7.7
B4 Severe Recombination 3.1 8.0
B5 Attenuated Nonsense 4.5 9.0
B6 Severe Missense 7.1 9.2
B7 Severe Missense 7.8 11.4
Group C
C1 Severe Missense 4.3 12.7
C2 Severe Nonsense 4.0 15.8
C3 Attenuated Missense 3.8 16.3
C4 Attenuated n.i. 6.8 16.7
C5 Attenuated Missense 15.5 18.7
C6 Attenuated Missense 15.2 18.8
C7 Severe Nonsense 4.1 27.0
Age at start of ERT: group A ≤5 years, group B >5 and ≤ 12 years, group C >12 years (n.i. = not identified).
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tered. The median follow-up duration was 2.9 (1.6-3.7)
years for group A, 3.3 (1.4-3.6) years for group B and 3.2
(0.8-3.6) years for group C. Data are separately reported
for liver and spleen in Tables 3 and 4 respectively, together
with the statistical analysis. The McNemar test applied
highlighted a significant amelioration of hepatomegaly
only for the patients of group B with 6 out of 7 patients
presenting no liver enlargement at the end of the study
(Table 3). No significant improvements were evidenced
for splenomegaly in all groups analysed (Table 4).
Analysis of all patients taken together (A + B +C) and of
all patients under 12 years of age (A + B) did not reveal any
significant improvements for both organs analysed.Cardiac valve disease
Figure 2 shows the prevalence and the severity of valve
regurgitation in the 27 patients enrolled in the study, be-
fore the beginning of the therapy, evidenced through
echocardiography. The mitral valve was the most in-
volved with 76% of the subjects affected, with a severity
score from 1 to 3; 38% and 32% of the patients presented
with regurgitation of the aortic and of the tricuspid
valves respectively (score 1÷2) while only in 9% of them
an involvement of the pulmonary valve was observed.
Figure 3 reports for each valve the percentage of pa-
tients for group A, B, C, A + B and A + B + C presenting
an improvement, a stabilization or a worsening of regur-













































































































Figure 1 Urinary GAG dosage. Urinary GAG values are reported for each subject as percentage with respect to the pre-ERT level. A: patients
aged ≤5 years, B: patients aged >5 and≤ 12 years, C: patients aged >12 years.
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Table 2 Statistical analysis of GAG percentage variation from pre-ERT values
Age group Time point from start of ERT n Median (minimum-maximum) p-value
A 1 yr ± 4 m 12 37.6 (7.8-76.0) 0.0005*
2 yrs ± 4 m 9 29.4 (3.9-92.1) 0.0039*
3 yrs ± 4 m 7 24.5 (13.7-81.8) 0.0156*
Last 13 25.4 (5.7-79.2) 0.0002*
B 1 yr ± 4 m 6 33.9 (17.1-88.1) 0.0313*
2 yrs ± 4 m 4 19.5 (17.4-36.0) 0.1250
3 yrs ± 4 m 4 19.2 (18.0-23.1) 0.1250
Last 7 18.2 (14.6-55.8) 0.0156*
C 1 yr ± 4 m 5 26.4 (8.9-38.8) 0.0625
2 yrs ± 4 m 4 16.5 (9.3-29.6) 0.1250
3 yrs ± 4 m 5 26.4 (5.7-35.1) 0.0625
Last 5 13.3 (5.1-28.2) 0.0625
A + B 1 yr ± 4 m 18 35.6 (7.8-88.1) < .0001*
2 yrs ± 4 m 13 20.2 (3.9-92.1) 0.0002*
3 yrs ± 4 m 11 21.0 (13.7-81.8) 0.0010*
Last 20 24.0 (5.7-79.2) < .0001*
A + B + C 1 yr ± 4 m 23 31.8 (7.8-88.1) < .0001*
2 yrs ± 4 m 17 20.0 (3.9-92.1) < .0001*
3 yrs ± 4 m 16 22.0 (5.7-81.8) < .0001*
Last 25 18.2 (5.1-79.2) < .0001*
Urinary GAG values are expressed at each time-point, from start of ERT as percentage with respect to the pre-ERT baseline level, taken as 100%. The number of
available samples considered in the calculation (n), the median value and minimum and maximum values, together with the p-value of the statistical test applied
(Wilcoxon signed rank test), are reported. Statistically significant values (p < 0.05) are marked with an asterisk.
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3.7) years for group C. The highest frequency of positive
outcomes was observed for the mitral valve with most
patients of all groups presenting an improvement or a
stabilization. A stabilization of the aortic valve regurgita-
tion was observed for most groups except for group A,
for which a worsening of the condition was registered.
Also for the tricuspid valve a stabilization of the condi-
tion for group A, A + B and A + B + C, or a balance be-
tween worsening and stabilization (group B and C) were
registered, while the high percentage of stabilization ob-
served in the pulmonary valve is ascribable to theTable 3 Contingency table and statistical analysis of hepatom
Group
Pre-post
Y-Y Y-N N-Y N-N
A 3 3 4 1
B 1 6 0 0
C 3 2 0 2
A + B 4 9 4 1
A + B + C 7 11 4 3
The category “Positive Outcomes” includes both YES-NO (Y-N: improvement) and N
and Pearson method and the p-value of McNemar test are reported. Statistically sig
n = 7, group C: n = 7.absence of involvement evidenced both before and after
therapy in all groups of patients.
ENT manifestations
Among all Ear, Nose and Throat (ENT) manifestations,
otological disorders, adenotonsillar hypertrophy and
sleep disorders of respiratory origin were taken into con-
sideration. Such variables were evaluated at pre-ERT
time, when available, and at the end of the study with a
median follow-up time of 3.0 (0.1-3.8) years for group A,






1.0 0.36 (0.109, 0.692)
0.03* 0.86 (0.421, 0.996)
0.50 0.57 (0.184, 0.901)
0.27 0.56 (0.308, 0.785)
0.12 0.56 (0.349, 0.756)
O-NO (N-N: stabilization) cases. Confidence intervals, calculated by the Clopper
nificant values (p < 0.05) are marked with an asterisk. Group A: n = 11, group B:





Y-Y Y-N N-Y N-N Proportion CI (95%)
A 0 1 3 5 0.63 0.67 (0.299, 0.925)
B 2 2 0 2 0.50 0.67 (0.223, 0.957)
C 2 3 0 2 0.25 0.71 (0.290, 0.963)
A + B 2 3 3 7 1.00 0.67 (0.384, 0.882)
A + B + C 4 6 3 9 0.51 0.68 (0.451, 0.861)
The category “Positive Outcomes” includes both YES-NO (Y-N: improvement) and NO-NO (N-N: stabilization) cases. Confidence intervals, calculated by the Clopper
and Pearson method and the p-value of McNemar test are reported. Group A: n = 9, group B: n = 6, group C: n = 7.
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with the statistical analysis, in Additional file 1. As for
otological disorders, none of the 3 groups separately
analysed showed a statistically significant improvement
at the end of the follow-up. About 50% of the entire
population (A + B + C) and 40% of the patients aged ≤12
years (A + B) showed an improvement of the otological
disease, or at least did not register a worsening of the
ear condition in the course of the treatment; however,
this did not result in any statistical significance.
Evaluation of adenotonsillar hypertrophy was per-
formed only for patients that did not undergo adenoton-
sillectomy. No statistically significant amelioration was
observed for the 3 groups separately analysed. In
addition, the analysis of the whole population examined
and of the patients under 12 years of age did not show
any statistical significance.
As for sleep disturbances of respiratory origin, the sep-
arate analysis of the 3 groups did not evidence any sta-
tistically significant amelioration due to the treatment,
as well as the analysis of the combined groups A + B + C
























Figure 2 Pre-ERT cardiac valve regurgitation. Percentage of patients pr
to Zoghbi et al. [18], before the beginning of ERT (n =21 for mitral and aorGrowth
To evaluate growth of children affected by MPS II and
treated with idursulfase, we collected height measure-
ments during the follow-up and calculated the z-scores
for each time-point for all patients of groups A and B
(Figure 4). Due to the older age, no height curves could
be analysed for the patients of group C. The regression
plot for group A is represented by a line with a slight
positive slope indicating that all patients tend to over-
come the mean value over the time, although oscillating
around the average (z-score = 0). On the opposite, group
B data are interpolated by a negative slope line located
below the average for all time-points considered (z-
score = −1.5÷−2), suggesting a decreasing growth rate
for this age group.
Data on weight for groups A and B are provided as
Additional file 2. In group A the regression line of
weight z-scores is positioned slightly above the average
(z-score = 0.53÷0.63) and is quite stable over the time.
On the opposite, in group B the slope line is negative as
Z-score values decrease during the follow-up from about






esenting valve regurgitation and related degree of severity according
tic valves, n = 22 for tricuspid and pulmonary valves).












































Figure 3 Post-ERT cardiac valve regurgitation. Percentage of patients of group A, B, C, A + B and A + B + C presenting an improvement, a
stabilization or a worsening of regurgitation of the mitral, aortic, tricuspid and pulmonary cardiac valves. Group A: n = 10, group B: n = 6, group
C: n = 6 for tricuspid and pulmonary valves, n = 5 for mitral and aortic valves.
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The evaluation of joint range of motion (JROM) of
upper limbs (shoulder and elbow) and lower limbs (knee
and ankle) is provided in Figure 5A and B respectively,
and it is expressed as stabilization, worsening or im-
provement of JROM with respect to the pre-ERT clinical
picture. One-third of the patients aged <12 years showed
an amelioration of upper limbs movements while no im-
provements were observed in lower limbs. In group C,
43% of patients evidenced an increased mobility of upper
limbs, while no patients showed improvements of lower
limbs. Hence, where a reduction of joint limitation was
registered this involved almost exclusively the upper
limbs, in particular the shoulders (with improved range
of abduction), as clearly evidenced in Figure 5A, al-
though no statistically significant amelioration was ob-
served for any of the groups analysed.
Statistical analysis of the entire population examined
(A + B + C) and of each single age group taken separ-
ately (A, B, C) also did not highlight significant im-
provement of JROM due to the treatment.
Distance covered in the 6-Minute Walk Test (6MWT)
This endurance test was administered rarely to the pa-
tients during the follow-up. The principal reason dealt
with the difficulty to obtain collaboration by thepatients, in particular in the youngest group. In
addition, during the follow-up most patients registered
a worsening of the psyco-motor delay with the conse-
quent inability to walk. Therefore, data are only avail-
able for 6 patients (Figure 6): 3 from group A, 2 from
group B and 1 from group C (this last one not is re-
ported in the figure due to unavailability of data of an
age-paired healthy population). In group A, all 3 pa-
tients showed a mean improvement of about 20% on the
distance covered; since this improvement might be
partly due to the increasing age and related ability to
walk, data obtained were compared with age-related
percentile of an healthy population. In group B, 1 pa-
tient improved (+37%) and the second one reduced
(−13%) the stretch walked. The single patient examined
from group C improved his performance of about 20%.
Overall, although a positive trend could be observed,
the paucity of data did not allow to draw any conclusions
about the efficacy of the therapy on this performance.
Neurological evaluation
Neurological analysis, including brain imaging, cognitive
tests and evaluation of seizures, is reported in Additional
file 3.
All patients of all groups presented neurological alter-































































Figure 4 Height z-scores. Regression plot for height z-scores before the start of ERT (time-point = 0) and after the start of ERT (time-points t >0)
for patient groups aged ≤5 years (A) and >5 and≤ 12 years (B).
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hydrocephalus requiring ventriculoperitoneal shunting; due
to the appearance of a marked stenosis of the cervical me-
dulla, a second patient from group A underwent decom-
pression surgery. In all 3 cases surgery was performed after
the start of ERT.
In group A, cognitive deterioration could be observed in
7 patients out of 11; 4 of them showed, at baseline, bor-
derline or mild cognitive delay, apparently stabilized, thus
we considered these cases as “attenuate” phenotypes. In
group B, 4 patients presented a cognitive decline while 2
patients showing a stable profile of mild mental delay were
assigned to the attenuated phenotype. In group C, 3patients presented a preserved cognitive function which
allowed a regular schooling, including university studies
for 2 of them.
In two patients of group A, seizures appeared during
ERT follow-up. In groups B and C, 5 more patients
showed seizures, already present in the pre-ERT phase
for 4 of them, while for 1 subject pre-ERT data were not
available. All subjects presenting seizures also showed
cognitive impairment.
No statistically significant amelioration was obtained
for any of the parameters observed; also the analysis of
A + B + C or A + B groups did not produce any statisti-
cally significant results.





















Figure 5 Evaluation of joint stiffness. Percentage of patients of group A, B, C, A + B and A + B + C presenting an improvement, a stabilization
and a worsening of joint stiffness for upper (A) and lower limbs (B).
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Biochemical and haematochemical laboratory parameters
regularly examined did not generally show notable
alterations.
The measurement of the FVC, scheduled for patients
aged 6–12 years, was rarely administered due to poor
collaboration of the patients because of their psycho-
motor delay and cognitive impairment.
For the remaining evaluations reported in the Mate-
rials and Methods section, no thorough analysis was per-
formed, given the incomplete set of data available.
ERT efficacy evaluation in severe versus attenuated
phenotypes
In Additional file 4 we report the analysis of the data ob-
tained by subdividing patients into severe (n = 17) and
attenuated (n = 10) phenotype. The reduction of urinary
GAG levels resulted significant at each time-point for se-
vere patients, after 1 and 3 years of treatment and at the


























Figure 6 Distance covered in the 6MWT. Distance covered before and a
represented as dotted lines, were taken from Lammers et al. 2008 [20].proportion of positive outcomes obtained by ERT was
found to be higher in severe vs attenuated patients for
several parameters. These included hepatomegaly (60%
of severe vs 50% of attenuated), splenomegaly (76.9% of
severe vs 55.6% of attenuated), otological disorders
(58.3% of severe vs 33.3% of attenuated), adenotonsillary
hypertrophy (75% of severe vs 20% of attenuated) and all
valve regurgitations except the mitral one (57% severe vs
86% attenuated). No differences in the percentage of im-
proved patients were observed for joint stiffness between
the 2 groups, since the great majority of the patients did
not obtain any ameliorations from ERT as well as for the
CNS abnormalities detected by brain imaging. Finally,
attenuated patients presented no cognitive function in-
volvement, as expected, no ENT-related sleep distur-
bances and no seizures.
Discussion
Until recently, treatment of Hunter Syndrome was only pal-










fter ERT. Reference values for healthy children aged 4–11 years,
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Therapy (ERT) protocol, employing a recombinant form
of idursulfase. Safety and efficacy of ERT have been pri-
marily evaluated by two randomized trials [9,10] and sub-
sequently by an open-label extension of the trial [21].
Since 2005 the HOS collects data on Hunter patients with
the intent to delineate the natural history of the disease
and to monitor safety and effectiveness of ERT. However,
several aspects still have to be fully considered. One of the
main issues is to understand whether early treatment
might importantly slow down the disease progression,
given that criteria for enrolment in clinical trials did not
imply any restrictions related to the age of the patients. In
addition, when the drug was released the majority of
Hunter patients went on treatment at any age; therefore an
extensive evaluation of the efficacy on paediatric patients re-
mains important to perform. To this aim, we here analysed,
as an independent evaluation, the efficacy of ERT, performed
with Elaprase®, administered weekly at a dosage of 0.5 mg/kg
in a paediatric population starting treatment earlier than 12
years of age. In parallel, a small population of subjects,
starting ERT later than 12 years of age, was enrolled.
In the last years two HOS reports on children younger
than 6 years were published [11,12]; however these stud-
ies presented several limitations mainly related to the
small number of patients evaluated [11] and/or the lim-
ited number of variables analysed [12].
Up to date, few independent reports were published,
among which a recent British study funded by the HTA
program [15], analysing 36 patients below 16 years of age
and 3 adults which evidenced only height improvements,
significantly associated to the duration of ERT. The au-
thors, however, stated that some of the variables assayed
were “hampered by a paucity of data related to both the
small number of affected patients recruited and lack of re-
cording of data on key outcomes for a substantial propor-
tion of the patients” [15].
The present study enrolled 27 patients, clustered in 3
groups according to the age at start of ERT (≤5 years
(group A), >5 and ≤12 years (group B and >12 years (group
C)) and classified as “severe” (17 cases) or “attenuated” (10
cases), on the basis of the clinical and neurological evalua-
tions. The percentage of severe patients was therefore 63%,
a proportion similar to that commonly described [22]. Our
population included 2 couples of siblings. The 2 subjects of
each couple, though presenting the same mutation and a
likely similar genomic background, showed a different level
of involvement for some of the organ systems analysed.
Interestingly, 2 non-sibling patients showing the same non-
sense mutation presented an attenuated and a severe
phenotype, respectively. This confirms the poor genotype-
phenotype correlation widely recognized for the disorder
[23], which usually complicates or hampers prognosis on
phenotype severity and/or disease progression.Our analysis on the efficacy of this ERT protocol in-
cluded several clinical parameters as well as laboratory
measurements mostly related to important peculiar clin-
ical signs of MPS II; thus, the chosen parameters pos-
sibly reflected the extent of disease progression.
In both groups of patients examined, aged ≤ 12 years,
we observed a significant urinary GAG reduction, while
such significant decrease was not measured in group C.
However, this result may be importantly affected by the
small number of patients examined in group C. Urinary
GAG decrease is widely used as indicator of therapeutic
efficacy in MPS II patients. However, how a decrease of
urinary GAG level might be related to the efficacy of the
drug on tissue and organ systems is still to be defined
[24]. Based on our observations, not always a decrease
of urinary GAG corresponds to an improvement of
other signs, as hepato and/or splenomegaly or to a gen-
eral amelioration of the clinical phenotype. Urinary
GAG measurement is a simple, quite inexpensive and
non-invasive procedure useful as diagnostic tool; its
value for treatment monitoring should be re-evaluated
or, at least, GAG results should be supported by the par-
allel evaluation of a second parameter.
Analyses of hepatomegaly and splenomegaly were per-
formed separately in our evaluation. Distribution of the
patients in groups of increasing age allowed to observe
that hepatomegaly can be detected in the course of MPS
II progression more precociously than splenomegaly. In
fact, in the pre-ERT phase of the analysis hepatomegaly
was described in 58% of the patients of group A and
splenomegaly in 9% of them; in group B 100% of the pa-
tients presented hepatomegaly and 33% splenomegaly; in
group C 71% of the patients presented both hepato- and
splenomegaly at start of treatment. Hepato/splenomeg-
aly is widely associated to the disease and monitored as
primary endpoint of ERT efficacy in MPS II patients [9].
In our analysis, a significant reduction of hepatomegaly
was registered for patients of group B, while we did not
detect a statistically significant reduction of splenomeg-
aly in all 3 groups of patients after treatment. This may
be partly due to the absence of spleen enlargement in
most of the patients examined in the pre-ERT phase,
which importantly reduced the size of analysable sam-
ples to 10 subjects. The recent study by the British HTA
[15] did not detect, in a population of more than 20 pa-
tients, any significant reduction of both hepato- and
splenomegaly, evaluated separately. However, such ana-
lysis was conducted on a follow-up of 12 and 24 months,
while in our study final evaluations were performed on
average 3 years after the start of ERT. In addition, the
HTA evaluation on hepato/splenomegaly was conducted
by palpation, which might be influenced by a certain de-
gree of subjectivity; our examination was always con-
firmed by an ultrasound evaluation of the abdomen.
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disease in the vast majority of the patients [25], we primar-
ily examined valvulopathies, which are the most frequently
assessed cardiac disease in MPS patients [26]. In particular,
we assessed valve regurgitation, a parameter more object-
ively evaluated than other cardiac measurements, and ob-
served that even most of the youngest patients were already
compromised in the pre-ERT analysis. Therefore, it would
be useful to include valvulopathy among the signs to con-
sider in the clinical suspect of Hunter Syndrome. According
to our study, this sign, seems to slightly benefit from the
treatment, leading to an improvement or to a stabilization
of the valve regurgitation (in particular of the mitral and of
the tricuspid valves), differently from what is reported by
recent studies, in which ERT seems to significantly reduce
the cardiac hypertrophy, but has limited effect on valve re-
gurgitation [15,27]. However, we need to take into consider-
ation that cardiac valves are connective tissue, thus missing
an important blood and ERT supply. In addition, heart dis-
ease in these patients is often treated with other concomi-
tant palliative medications; this could hamper the correct
analysis and the detection of a potential ERT efficacy on
this organ.
Respiratory evaluation in itself is sometimes difficult
to carry on in these patients since FVC is applicable only
to “attenuated”, collaborating subjects. Other parameters,
strictly associated to the respiratory tract analysis, but not
requiring or requiring less collaboration by the patients,
were analysed in the present study, such as otological dis-
orders including deafness, adenotonsillary hypertrophy
and sleep disorders. None of them seemed to receive sig-
nificant improvements by ERT administration.
Growth retardation is a peculiar feature of Hunter
Syndrome. In MPS II patients, height is normal up to
approximately 8–10 years of age and then it gradually
decreases attesting on values below the third percentile
[28-31]. Similarly, weight falls within the reference stan-
dards up to about 15 years of age, showing later on a
negative trend [29,30]. In the present study growth pat-
terns were analysed in terms of both height and weight.
Height z-scores of Hunter patients under ERT, plotted
vs treatment duration, showed that the youngest patients
remained within normal values, ranging between −1 and +1
z-scores, but with the tendency to improve slightly over
time. For group B the trend is negative with z-scores ranging
from −3.5 to 1.5 with data distribution similar to that re-
ported by Jones [31], for a group of patients aged 8–15
years, in the post-ERT period. The analysis of weight
data confirms the negative trend described for this an-
thropometric variable in untreated Hunter patients
[28-31] but suggests a potential reduction of this nega-
tive pattern mediated by ERT. This last observation
could be particularly interesting since up today no data
on the effect of idursulfase on weight are reported inthe literature. Unfortunately, since control paired data
on untreated patients were not available, a statistical
analysis on the effect of ERT on both height and weight
was not feasible.
Joint stiffness is another typical sign of Hunter Disease
[32]. Evaluation performed in our population at baseline
level showed a deep involvement of both upper and lower
limbs in all patients. Improvements observed after treat-
ment involved mainly the upper limbs, specifically
abduction movements, with some stabilization, while no
improvements were described for the lower limbs. Ameli-
oration of upper limbs is of great importance for patients,
who may acquire some autonomy in their daily functions,
as well as for their families and caregivers. This improve-
ment of potential performances may therefore determine
an improvement of their quality of life.
The 6MWT test is considered a measure of functional
capacity [9] and has been recently re-allocated from the
secondary to the primary outcome evaluations for
Hunter patients on ERT [33,34], although a significant
limitation to its use is the poor compliance of Hunter
patients [24]. Muscular-skeletal system is one of the dis-
tricts involved in the 6MWT, together with heart, brain
and respiratory functions. Unfortunately, in our study
such evaluation could be performed only for a few pa-
tients; also, most of them was affected by a severe form
of the disease. Our experience suggests that improve-
ments of this test might be positively influenced mainly
by respiratory function since both lower limbs extensi-
bility and CNS may benefit from ERT to a lesser extent.
Therefore, an amelioration of the respiratory functions
may also be investigated by administering the 6MWT in
compliant patients.
MPS II presents an important clinical heterogeneity;
traditionally two phenotypes, attenuated and severe,
have been reported. The distinguishing factor between
the two forms is the presence, or absence, of progressive
intellectual deterioration [4]. In a recent detailed de-
scription of a large cohort of patients, the down-slanting
course was evident by 60 months of age at the latest,
usually preceded by a plateau phase [35]. Approximately
two thirds of the patients with diagnosis of MPS II will
develop progressive neurodegeneration [36]. In a recent
study of 36 Italian patients, some of the common brain
and spinal cord features [revealed by Magnetic Reson-
ance Imaging (MRI) and/or Computerized Tomography
Scanning (CT-scan)] as WMAs, atrophy and/or commu-
nicating hydrocephalus and cranial vault hyperostosis,
were observed to correlate with the severe Hunter
phenotype. An enlarged cisterna magna was observed
more frequently in the attenuated phenotype [5]. In the
same study, ERT introduction did not seem to modify
the disease progression in terms of WMAs, atrophy/
communicating hydrocephalus and spinal stenosis. Our
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parameters evaluated. Seizures are common neurologic
complications in patients with MPS II. Schwartz and
colleagues in a large cohort of 77 patients with Hunter
Disease reported an incidence of 13% for seizures. They
described a higher recurrence in subjects with the severe
form, after the age of 10 years [28]. Seven of the patients
of our study (26%) presented epilepsy, either pre-
existent or with onset after the start of ERT. All of them
were affected by the severe form of the disease and ERT
did not show a positive effect on seizure. However, ef-
fects of ERT on CNS were not expected due to the in-
ability of Elaprase® to cross the Blood–brain Barrier
(BBB) [37] and the recent multicentre study by Manara
and colleagues [5] stated that even tissues which do not
localize beyond the BBB, as head bones and meninges,
do not seem to benefit from ERT.
To minimize biases caused by the small sample size of
the 3 groups examined separately, we also evaluated all
subjects enrolled, taken together as one group (n = 27),
and all children up to 12 years of age at start of ERT
(n = 20). However, these evaluations did not significantly
change the results obtained on the clinical parameters
examined with respect to the analysis conducted on the
3 separate groups.
Finally, ERT efficacy was also evaluated in relation to the
severity of the disease, distinguishing “severe” (n = 17) from
“attenuated” (n = 10) phenotypes. The analysis showed a
slightly higher improvement/stabilization of parameters as
GAG level, hepatomegaly, splenomegaly, otological disor-
ders, adenotonsillar hypertrophy and cardiac valve regurgi-
tation (except mitral valve) in severe vs attenuated patients.
This may be due to the presence of more advanced clinical
signs in severe patients at start of treatment, for which an
amelioration due to ERT could result more evident. Again,
no differences between the two groups were detected for
joint stiffness and CNS abnormalities by brain imaging,
confirming that ERT does not efficiently act on these clin-
ical signs. In addition, our study confirmed that attenuated
patients, together with no cognitive progressive deterior-
ation, present no seizures. These findings should be more
deeply evaluated to state if they represent sufficient evi-
dence to exclude a prognosis of severe progression of the
disease.
Strict monitoring of patients on ERT should be de-
signed according to specific shared guidelines stating
timing/frequency of specific evaluations, with the final
aim to differentiate those subjects who may benefit from
ERT from those who probably will not. Such monitoring
is becoming mandatory for clinical, ethical and eco-
nomic reasons. The high costs of orphan drugs and in
particular of orphan biopharmaceuticals is not a new
issue, as stated recently by some articles [38,39]. The
average cost of idursulfase treatment in Italy exceeds300.000 €/year for a 30 kg patient and proportionally in-
creases with patients’ weight; compared to this, the costs
of treatment monitoring appear almost insignificant and
necessary to assess drug efficacy in every single patient.
The identification of other biological markers, easy to
access and affordable, to investigate the response to
therapy when correlated to clear clinical signs, should be
strongly encouraged.
Finally, as recently suggested for the severe form of the
disease, possible criteria of discontinuation of the therapy
should be identified and shared by caring physicians, and
clearly explained to the family before ERT is initiated [40].
Conclusions
In our Hunter population, Enzyme Replacement performed
earlier than 12 years of age did not show to determine any
more efficacy than when applied at an older age, except for
urinary GAG, significantly reduced only in the younger
groups, likely due to the low number of patients examined
for the oldest group of age. No differences between the 2
populations were registered for hepatomegaly or splenomeg-
aly, showing an identical proportion of positive outcomes.
Some other parameters evaluated showed to take advantage
from the treatment, although not significantly.
Also, efficacy of ERT in Hunter patients has revealed to
be extremely subjective, despite a widely accepted common
protocol (same dose/kg of body weight, time-schedule and
velocity of infusion). Therefore, both dose and frequency
regimens of administration likely need to be tailored to
every single patient, based on his clinical picture.
Additional files
Additional file 1: Analysis of ENT manifestations. Tables reporting
the statistical analysis of otological disorders (group A: n = 9, group
B: n = 3, group C: n = 6), adenotonsillar hypertrophy (group A: n = 6,
group B: n = 1, group C: n = 2) and sleep disorders of respiratory origin
(group A: n = 8, group B: n = 3, group C: n = 5).
Additional file 2: Analysis of weight z-scores. Regression plot for
weight z-scores before the start of ERT (time-point = 0) and after the start of
ERT (time-points t >0) for patient groups aged 0–5 years (n = 11) (A) and
aged 6–12 years (n = 7) (B).
Additional file 3: Analysis of neurological compartment. Tables
reporting the statistical analysis of neurological data on brain imaging
(group A: n = 7, group B: n = 6, group C: n = 6), cognitive tests (group
A: n = 11, group B: n = 6, group C: n = 3), and seizures (group A: n = 5,
group B: n = 2, group C: n = 4).
Additional file 4: Analysis of severe versus attenuated patients.
Statistical analysis tables of clinical variables for severe and attenuated
patients. Urinary GAG analysis: severe: n = 16, attenuated: n = 9;
Hepatomegaly: severe: n = 15, attenuated: n = 10; Splenomegaly: severe:
n = 13, attenuated: n = 9; Cardiac valves regurgitation: severe: n = 15
(n = 14 for mitral and aortic valves), attenuated: n = 7; Otological
disorders: severe: n = 12, attenuated: n = 6; Adenotonsillar hypertrophy:
severe: n = 10, attenuated: n = 6; Sleep disorders: severe: n = 10,
attenuated: n = 6; Joint stiffness: severe: n = 15, attenuated: n = 7; CNS
abnormalities by brain imaging: severe: n = 12, attenuated: n = 7;
Cognitive function involvement: severe: n = 11, attenuated: n = 9; Seizure:
severe: n = 9, attenuated: n = 2.
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